This is a video synopsis/summary of a panel discussion involving Marla Dubinsky, MD; David Rubin, MD; Miguel Regueiro, MD; Remo Panaccione, MD, FRCPC; and Sara Horst, MD, MPH.

In this discussion, the participants delve into the classification of therapies for Crohn's disease (CD), focusing on tumor necrosis factor (TNF) inhibitors and anti-integrins. The conversation initiates by addressing the effectiveness of different drugs within the TNF inhibitor class. The speaker highlights the 3 approved options – infliximab, adalimumab, and certolizumab – providing a historical context, administration methods, and factors influencing the choice of therapy.

The speaker emphasizes the importance of tailoring treatment to individual patients based on factors such as severe Crohn's complications, perianal disease, or extraintestinal manifestations. He addresses patients' concerns about the long-term commitment to therapy, emphasizing the need to focus on improvement before considering duration.

The discussion then shifts to anti-integrins, specifically vedolizumab, approved for Crohn's disease. The speaker discusses patient selection criteria, such as those who have not received a biologic before, non-smokers, and those without prior surgery. She highlights the success of anti-integrins in colonic disease and post-operative patients, citing data on decreased endoscopic recurrence.

The participants acknowledge the nuanced nature of treatment decisions and the evolving data guiding their choices. The conversation underscores the importance of closely monitoring patients and considering alternative therapies if needed.

In summary, the participants discuss the rationale behind choosing TNF inhibitors or anti-integrins based on patient characteristics and response, emphasizing personalized treatment strategies and the evolving understanding of therapeutic options.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.